CAR-T and The Rise of the Cellicon Valley
CELLICON VALLEY 21': THE FUTURE OF CELL AND GENE THERAPY - CLICK HERE TO MORE INFORMATION
View Pictures of the Conference
Photographs by Ed Cunicelli
View Video of the Conference
Day 1
Day 2 - Part 1
Day 2 - Part 2
Thursday, May 9 and Friday, May 10, 2019
Overview
CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The recent approval of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in CAR T-cellular therapy and hematopoietic stem cell transplantation (HSCT) have been assembled to discuss the development and implementation of this therapy and to weigh in on current applications, best practices, novel strategies and future developments for CAR T cells.
Who Should Attend
These activities are intended for both adult and pediatric hematologist-oncologists, medical oncologists, hematologists, hematopathologists, immunologists, immunobiologists, transfusion medicine, researchers and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of adult and pediatric patients with cellular therapies are also invited to attend. Patients and their caregivers, family members, advocates and the general public who may benefit from understanding current cellular therapy approaches are also invited.
Learning Objectives
Upon completion of this symposium, participants should be able to:
- Identify current application of CAR T-cell therapy including: accurate patient selection, manufacture and treatment administration
- Implement guidelines for patient management of toxicities of CAR T-cell therapies including cytokine-release syndrome
- List factors in overcoming resistance with novel CAR strategies
- Describe gene delivery and editing for CARs
- Identify the latest targets and technologies for CARs
- Identify the current status of globalization of CAR T-cell therapies and identify principles in ethics of patient access
- Describe current approaches in treatment and supportive care for hematopoietic stem cell transplantation (HSCT) in pediatric patients with nonmalignant conditions
- Identify the latest evidence based standards in nursing care resulting from the recent advances in cell therapy and transplant